Cyclerion to Host Webcast Investor Event on Cardiometabolic Programs on September 17
This first Cyclerion live investor event will focus on praliciguat, the company’s investigational, orally administered, once-daily systemic sGC stimulator designed for the treatment of serious cardiometabolic diseases. External subject matter experts – Dr. James Udelson of
Professional investors and equity research analysts are invited to attend the event in person. Please contact Jessi Rennekamp at firstname.lastname@example.org for additional information.
A webcast replay will be available on the Cyclerion website beginning approximately two hours after the event and will be archived for 21 days.
About Cyclerion Therapeutics
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion is advancing its portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements about the anticipated timing of release of data from our clinical trials. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those listed under the “Risk Factors” section and elsewhere in our Registration Statement on Form S-1 filed on
Brian Cali, (857) 338-3262
Jessi Rennekamp, (857) 338-3319
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/06060dbc-ed8f-46e2-af45-bcead4cc40a8
Source: Cyclerion Therapeutics, Inc.